Aspirin may increase survival after colon cancer

June 13, 2016

It is well known that aspirin has analgesic and fever-reducing properties. However, this drug may also increase the likelihood of surviving colon cancer.

Kjetil Taskén, professor at the Faculty of Medicine, is one of the authors of a study that has investigated the association between the use of and colon cancer.

The study shows that aspirin can be used to reduce mortality among colon cancer by 15 to 25 per cent.

On Tuesday, the study was published in the Journal of Clinical Oncology and reviewed in the VG daily.

"This is an interesting finding, because aspirin is a cheap with few adverse effects. The finding may therefore have a potential benefit for the approximately 4000 patients who are diagnosed with colon cancer each year," says Taskén, who is also director of the Biotechnology Centre in Oslo (BiO) and the Norwegian Centre for Molecular Medicine (NCMM).

This is the first study to provide a clear answer about the effect of aspirin in colon cancer patients treated post-diagnosis. In their study, Taskén and his collaborators also show that other contributory factors play a lesser role.

The study is based on figures from the Norwegian Cancer Registry and the Norwegian Prescription Database. More than 23,000 people from all over the country were included, which makes this study unique.

Cost/benefit

Aspirin is known to prevent carcinogenesis in the intestine, but whether this drug should be used to prevent cancer in the healthy population has been a matter of controversy. This is because this drug may also cause brain haemorrhages and gastric ulcers in a small minority of people.

But what if the drug could be used to prevent a relapse in patients who have been treated for ?

"Because the patients' immune system can mobilize anti-tumour immunity only after exposure to cancer cells, and because this anti-tumour immunity is inhibited by prostaglandin, our hypothesis was that the effect of aspirin was perhaps even greater after someone had suffered from cancer. In other words, that cancer can be prevented from re-occurring in the patient," Taskén explains.

"Moreover, the cost-benefit assessment will completely change, because the risk of a relapse is much higher than the risk of initial onset of cancer," he continues.

On 6 June, Kjetil Taskén received the King Olav V Cancer Research Award 2016 for his work on immunotherapy.

The King Olav V Cancer Research Award is given by the Norwegian Cancer Society to researchers who have helped promote the quality and scope of Norwegian cancer research.

The jury's statement says that "he has greatly contributed to the understanding of immuno—oncology, and this work will become even more relevant in the development of the next generation of immunotherapy."

Explore further: Low-dose aspirin tied to longer colon cancer survival

More information: S. J. Bains et al. Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study, Journal of Clinical Oncology (2016). DOI: 10.1200/JCO.2015.65.3519

Related Stories

Low-dose aspirin tied to longer colon cancer survival

June 2, 2016
(HealthDay)—Colon cancer patients who take low-dose aspirin may have a somewhat better chance of surviving the disease, a large study hints.

Regular aspirin use may protect against bile duct cancer

May 9, 2016
(HealthDay)—Regular aspirin use may lower the risk of bile duct cancer, according to a study published online April 26 in Hepatology.

Aspirin use appears linked with improved survival after colon cancer diagnosis

March 31, 2014
Taking low doses of aspirin (which inhibits platelet function) after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.

Aspirin use may help prevent bile duct cancer, study finds

April 19, 2016
A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published ...

Aspirin use not found to benefit prostate cancer mortality

April 14, 2015
(HealthDay)—Aspirin use does not appear to reduce the risk of mortality associated with prostate cancer, according to research published in the April issue of The Journal of Urology.

Expert panel reaffirms daily aspirin's use against heart disease, colon cancer

April 12, 2016
(HealthDay)—People in their 50s who are at increased risk of heart disease should take a low-dose aspirin each day to reduce their risk of both heart disease and colon cancer, the U.S. Preventive Services Task Force (USPSTF) ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.